This article is more than 5 years old. Information may no longer be current.

Novel HF therapy associated with reduction in 30-day rehospitalizations

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ORLANDO, Fla. — A novel HF therapy reduced 30-day readmissions after hospitalization for HF compared with enalapril, according to new data from the PARADIGM-HF study.

Researchers conducted a post-hoc analysis of PARADIGM-HF to determine whether patients with HF with reduced ejection fraction (HFrEF) assigned sacubitril/valsartan (Entresto, Novartis), an angiotensin receptor-neprilysin inhibitor, had a lower rehospitalization rate compared with those assigned enalapril, an ACE inhibitor.

In PARADIGM-HF, 8,399 patients with HFrEF were randomly assigned sacubitril/valsartan 200 mg twice daily or enalapril 10 mg twice daily. In the present analysis, researchers reviewed data for 2,800 hospitalizations among 1,638 patients. They presented their findings at the American Heart Association Scientific Sessions.

The outcomes of interest were rehospitalization for HF within 30 days of discharge, both investigator-reported and adjudicated.

According to the investigator-reported data, there were 1,545 hospitalizations during the study period in the enalapril group and 1,255 in the sacubitril/valsartan group. Of these rehospitalizations, 12% in the enalapril group vs. 8.7% in the sacubitril/valsartan group occurred within 30 days (unadjusted OR = 0.69; 95% CI, 0.54-0.89; random-effects OR = 0.66; 95% CI, 0.49-0.89).

According to the adjudicated data, there were 1,082 hospitalizations in the enalapril group vs. 867 in the sacubitril/valsartan group, with a 30-day rehospitalization rate of 9.8% for the enalapril group vs. 7.5% for the sacubitril/valsartan group (unadjusted OR = 0.75; 95% CI, 0.54-1.03; random-effects OR = 0.7; 95% CI, 0.47-1.03).

Scott Solomon

Similarly, according to the investigator-reported data, there were 871 patients in the enalapril group and 767 in the sacubitril/valsartan group who were rehospitalized within 30 days, for a rate of 7.9% of patients in the enalapril group and 5.6% in the sacubitril/valsartan group (OR = 0.69; 95% CI, 0.47-1.02). According to the adjudicated data, the enalapril group had 659 patients hospitalized, 6.4% of whom were rehospitalized within 30 days, and the sacubitril/valsartan group had 546 patients hospitalized, 4.8% of whom were rehospitalized within 30 days (OR = 0.73; 95% CI, 0.44-1.21).

“In [HF], lower readmission rates may correlate with improved patient prognosis and lower costs to the health care system,” Scott Solomon, MD, director of noninvasive cardiology at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, said in a press release issued by Novartis. “By reducing both first and subsequent hospital admissions, we can reduce the health and economic burden associated with the reduced ejection form of this condition.” – by Erik Swain

Reference:

Solomon S, et al. Abstract 542. Presented at: American Heart Association Scientific Sessions; Nov. 7-11, 2015; Orlando, Fla.

Disclosure: The PARADIGM-HF study was funded by Novartis. Solomon reports receiving a research grant from and consulting or serving on an advisory board for Novartis.